Melanotan 1 Research: Clinical Trials, Mechanism & Safety Data
Melanotan 1 — also known as afamelanotide or MT-1 — is a linear 13-amino-acid analogue of α-MSH with a multi-decade human clinical trial record. Unlike Melanotan 2, it is highly selective for the MC1R receptor on skin pigment cells and is the research peptide that became the FDA-approved medicine Scenesse.
Mechanism of action
Melanotan 1 is a linear 13-amino-acid analogue of natural alpha-melanocyte-stimulating hormone (α-MSH). Two amino-acid substitutions make it more stable and potent than the natural hormone.
It is highly selective for the melanocortin-1 receptor (MC1R) located on melanocytes — the skin cells that produce pigment. This selectivity is what separates it from the broader receptor profile of Melanotan 2.
Activating MC1R switches melanin production toward eumelanin, the dark brown pigment that absorbs UV and scavenges free radicals, rather than pheomelanin, the reddish pigment linked to greater UV damage risk.
Because the resulting pigment layer physically blocks and scatters light, Melanotan 1 provides biological photoprotection — the mechanism that carried it from peptide research to the approved medicine Scenesse.
The studies
The published Melanotan 1 literature covers four major strands: photoprotection in the rare light-intolerance disorder EPP, synergistic tanning with reduced UV exposure, human pharmacokinetics across different delivery routes, and cellular anti-inflammatory / DNA-repair effects.
Human photoprotection
Erythropoietic protoporphyria (EPP) — pain-free light exposure
EPP is a rare genetic disorder in which porphyrin accumulation makes light exposure trigger severe burning pain and skin lesions. Researchers tested whether a slow-release afamelanotide implant could restore tolerance to daylight.
Multi-centre, double-blind, placebo-controlled · 16 mg bioresorbable subcutaneous implant (Scenesse) · 6-month observation
- 69.4 h
- Pain-free light exposure
- 40.8 h
- Placebo comparison
- ~50% fewer
- Severe phototoxic reactions
median over 6 months
Benefits shown in the data
- Treated patients recorded a median 69.4 hours of pain-free sun exposure over six months versus 40.8 hours on placebo.
- Severe phototoxic skin reactions fell by roughly half.
- The effect allowed previously housebound patients to spend meaningful time outdoors in daylight without triggering phototoxic pain crises.
- This is the pivotal evidence base on which the 16 mg Scenesse implant was approved for adult EPP patients.
- The benefit is sustained-release pharmacology: the implant steadily releases peptide, avoiding the sharp peaks and troughs of liquid injection.
Synergistic tanning
Synergistic tanning response & skin damage defence
University of Arizona researchers tested whether Melanotan 1 could safely darken skin while reducing the total UV dose needed for a tan, with the long-term aim of lowering skin-cancer incidence linked to sun-seeking behaviour.
Three Phase 1 randomised controlled trials · daily subcutaneous injections plus controlled solar UV exposure versus light alone
- 50% less
- Sun exposure needed
- 47% fewer
- Sunburn cells
- +3 weeks
- Tan persistence
for identical pigment depth
versus controls
Benefits shown in the data
- The peptide acted synergistically with light: tans were deeper and lasted at least three weeks longer than in controls.
- Participants needed half the usual sun exposure time to reach the same pigment depth.
- Histology showed 47% fewer sunburn cells, the marker of UV-induced keratinocyte damage.
- The pigment produced was predominantly eumelanin, the darker, more UV-absorbent melanin type.
- Melanotan 1 does not replace UV entirely in these studies; it amplifies the tanning response so less UV damage is required.
- Reported side effects were limited to transient facial flushing and mild nausea.
Pharmacokinetics
Bioavailability screening — IV, sub-Q and oral
To understand how the peptide behaves when delivered outside the slow-release implant, researchers compared intravenous, subcutaneous and oral administration in human crossover trials.
Comparative human crossover trials · intravenous (IV), subcutaneous (sub-Q) and oral (PO) dosing tracks
- 100%
- Sub-Q bioavailability
- 0.07–0.79 h
- Absorption phase
- 0.8–1.7 h
- Elimination half-life
- Zero
- Oral detection
relative to IV
rapid onset
no measurable blood levels
Benefits shown in the data
- Subcutaneous administration matched intravenous availability, giving a predictable plasma spike.
- The peptide clears quickly (short half-life) while leaving a longer-lasting cellular tan footprint.
- Oral dosing produced no detectable blood levels, confirming the peptide is broken down in the gut.
- The rapid absorption and short half-life explain why the approved medicine uses a slow-release implant rather than frequent liquid injections.
- These numbers describe how the compound moves in the body; they do not translate into a dosing recommendation for research vials.
Cellular mechanisms
Anti-inflammatory action & DNA repair support
UV radiation fractures cellular bonds and triggers inflammation. Researchers tested whether Melanotan 1 could speed DNA repair and reduce oxidative stress in human melanocyte cells.
In-vitro human melanocyte assays · cells exposed to UV radiation and treated with Melanotan 1
- Enhanced
- DNA repair
- Reduced
- Oxidative stress
- Quieted
- Inflammatory pathways
nucleotide excision repair
Benefits shown in the data
- MC1R activation raised intracellular cyclic AMP (cAMP), turning on genes involved in DNA repair.
- The cells showed faster nucleotide excision repair, the pathway that fixes UV-damaged DNA fragments.
- Pro-inflammatory signalling was reduced, suggesting an internal anti-inflammatory effect against light-induced trauma.
- These are cell-culture findings, so they establish mechanism rather than proven human skin protection.
- They help explain why the peptide is studied for photoprotection beyond simple pigment darkening.
Storage & handling
Melanotan 1 is supplied as a lyophilised powder. Keep sealed vials refrigerated or frozen, protected from light and moisture.
Reconstitute with bacteriostatic water directed slowly down the inner wall of the vial and swirl gently until clear. Do not shake.
Store reconstituted solution at 2-8 °C, shielded from light, and use within the stability window set by your lab's standard operating procedures.
Delivery context: approved implant versus liquid research vials
The human clinical data above comes from two very different delivery formats. Understanding the distinction is essential when reading the literature.
| Format | What the trials used | Research context |
|---|---|---|
| 16 mg slow-release implant (Scenesse) | FDA/EMA-approved for adult EPP; inserted every ~60 days | This is the format behind the Phase 3 photoprotection data. Side effects in formal trials were mild and transient: facial flushing, headache and brief nausea after placement. |
| Injectable liquid / nasal-spray research vials | Sold online as research chemicals; not approved medicines | These bypass the controlled-release profile of the implant. Because they are unregulated, potency, sterility and stability are not assured. Users with uneven mole distribution may also notice patchy hyperpigmentation. |
Melanotan 1 research context
A few points help readers interpret the data accurately.
Approved medicine versus research products
Scenesse (afamelanotide) is an approved 16 mg implant for EPP. Injectable liquid and nasal-spray products sold online as Melanotan 1 are unregulated research chemicals and are not the approved product.
Melanotan 1 is not Melanotan 2
Melanotan 2 crosses into the brain more readily and activates a wider range of receptors, which is why it is associated with nausea, appetite suppression and erectile effects. Melanotan 1 is far more selective for MC1R on skin pigment cells.
Research use only
Material supplied by Peptides Lab SA (PTY) Ltd is strictly for laboratory research and is not for human or veterinary use.
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.